The diagnostic gap the study addresses is well known to anyone who treats respiratory disease in early childhood. For adolescents and adults, and for children aged six years and older, asthma diagnosis follows well-established international guidelines built around spirometry, a test that measures how much air a person can exhale and how quickly. But spirometry is generally impractical below school age, and even oscillometry, a gentler technique that measures airway resistance during quiet breathing, cannot be reliably performed in children under three. As a result, diagnosing a wheezing toddler depends almost entirely on clinical judgment: repeated specialist assessments over months, the pattern of response to bronchodilators and inhaled corticosteroids, family history of atopy, and the exclusion of alternative causes. The authors argue that in this diagnostic gray zone, molecular indicators measurable in a simple blood sample could meaningfully sharpen the characterization and diagnosis of pediatric asthma.

To hunt for such indicators, the research team, led by Natalia Rzetecka-Mańka of Poznan University of Medical Sciences together with colleagues in Poznań and Kalisz, assembled four patient groups. Twenty-nine children had asthma; thirty-seven had asthma together with an IgE-dependent allergy; twenty had an IgE-dependent allergy alone; and twenty-seven controls had recurrent respiratory infections but no clinical signs of asthma or allergy. Every diagnosis was made by a pediatric allergist, with asthma requiring at least three episodes of bronchial obstruction, documented improvement after short-acting beta-agonists or inhaled glucocorticosteroids, and evaluation by a specialist on at least two occasions across a six-month observation window. Allergy status was confirmed by matching clinical symptoms with positive IgE results, using a panel covering thirty selected allergens. The research was conducted in accordance with the Declaration of Helsinki and approved by the Bioethics Committee of Poznań Medical University.

The analytical workhorse of the study was liquid chromatography coupled to tandem mass spectrometry, a technique that separates amino acids in a sample and then detects and quantifies each one with high specificity. Serum samples, collected into clotting-activator tubes, centrifuged and stored at minus eighty degrees Celsius, were processed with a certified clinical kit from Chromsystems. After protein precipitation and centrifugation, five microliters of each prepared sample were injected into an Agilent high-performance liquid chromatograph coupled with a Sciex 5500 QTRAP mass spectrometer operating in positive electrospray ionization mode. Each run lasted just nineteen minutes, and a quality-control sample was analyzed for every ten real samples, with relative standard deviations below ten percent confirming measurement precision. The method quantified twenty-six amino acids in total: nineteen of twenty-one proteinogenic amino acids and seven of twenty-eight non-proteinogenic ones, after excluding compounds that fell below the limit of quantification or showed more than fifteen percent missing data.

When the numbers came back, one molecule stood out. Asparagine concentrations were significantly higher in children with asthma than in children with asthma plus IgE-dependent allergy, with a p-value of 0.025. Asparagine also distinguished children with asthma from the non-asthmatic, non-allergic control group, at a p-value of 0.017. A second compound, the non-proteinogenic amino acid alpha-aminobutyric acid, separated the asthma group from controls with a p-value of 0.011. Intriguingly, the asthma-only group showed higher concentrations of both asparagine and alpha-aminobutyric acid in every comparison where the differences reached significance. No other amino acids, including arginine, long considered a classic amino acid biomarker of asthma through its role in nitric oxide metabolism, differentiated the groups in this cohort.

The asparagine finding gains biological weight from a rapidly expanding immunology literature. Asparagine, a non-essential amino acid synthesized from aspartate by the enzyme asparagine synthetase using glutamine as an amide donor, has emerged in recent years as a critical regulator of T cell immunity. Work published in Nature Cell Biology showed that asparagine potently enhances the activation of CD8-positive cytotoxic T cells: the higher the asparagine level, the stronger the activation, with the tyrosine-protein kinase LCK acting as a natural sensor of amino acid sufficiency within T cell receptor signaling. Other researchers have demonstrated that CD8-positive T cells require external asparagine to survive, grow, and undergo the metabolic reprogramming that accompanies activation, and that T cell receptor stimulation leads to substantial T cell death when both asparagine and glutamine are lacking. Because CD8-positive T cells accumulate in the airways of asthma patients, particularly in the context of viral infections and other intracellular pathogens, and because cytokines such as IL-2 can activate these cells and shape inflammation severity, elevated serum asparagine could plausibly reflect and even sustain the inflammatory processes driving asthma.

The authors also note the striking contrast with the compound’s better-known role. Asparagine is far more famous in oncology, where proliferating cancer cells consume it voraciously and where the enzyme asparaginase, which hydrolyzes asparagine to aspartate, forms the backbone of therapy for certain leukemias. Until now, asparagine had not been reported as a discriminatory feature in any respiratory disease. Alpha-aminobutyric acid carries its own intriguing pedigree: a byproduct of the biosynthesis pathways for methionine, threonine, serine, glycine and cysteine, it has been linked to liver disease, gut microbiome dysbiosis and sepsis, and a 2023 study suggested it can inhibit the activation and pro-inflammatory function of M1 macrophages, protecting against sepsis and inflammatory bowel disease in experimental models. The current study is, to the authors’ knowledge, the first to report elevated alpha-aminobutyric acid in young patients with asthma, opening an entirely new question about its role in airway inflammation.

Context matters when weighing these results against the existing metabolomic literature. Previous amino acid profiling studies in childhood asthma, including work comparing asthma with food allergy, atopic dermatitis, and exacerbation-prone phenotypes, did not identify asparagine or alpha-aminobutyric acid as significant discriminators, and only one earlier study found higher asparagine concentrations in a subgroup of asthma patients, specifically those less prone to exacerbations. The authors attribute the discrepancies partly to methodological differences: targeted versus untargeted approaches, serum versus plasma sampling, and heterogeneous comorbidities across study populations. They caution that their own control group consisted of children with recurrent respiratory infections rather than entirely healthy children, and that serum amino acid concentrations can be influenced by diet, age, concurrent infections and medications.

The team is candid about the exploratory nature of the work. With relatively small groups and multiple statistical comparisons, the reported p-values require validation in independent, larger cohorts, and the authors explicitly frame the study as a starting point rather than a diagnostic endpoint. They leave open a fundamental question: is asparagine an indicator of active disease, or a consequence of the respiratory changes that asthma produces? Answering it, they suggest, will require integrating metabolomic data with molecular pathway analyses of the immune response, alongside monitoring of amino acid levels in relation to age and diet in young children, whose nutritional needs shift rapidly in the first years of life.

Even so, the study carves out a distinctive position in the literature. It is, according to the authors, the first to measure a broad panel of free amino acids across four groups of children aged six months to five years, precisely the population in which asthma diagnosis remains most uncertain and molecular markers hold the greatest potential value. If asparagine’s association with childhood asthma holds up under validation, it could point toward blood-based tools for early risk stratification and for distinguishing asthma phenotypes in preschoolers, potentially reshaping how clinicians approach wheezing infants and toddlers long before they can blow into a spirometer. For a disease that affects millions of children worldwide and whose burden is growing amid air pollution and climate change, even a single amino acid may prove to be a thread worth pulling.

Subject of Research: Amino acid metabolomic profiling in preschool children with asthma and IgE-dependent allergy

Article Title: Comparative analysis of amino acid profiles across pediatric groups stratified by asthma and IgE-dependent allergy showed differences in serum asparagine levels

Article References: Rzetecka-Mańka, N., Pajewska-Szmyt, M., Matysiak, J., Sobkowiak, P., Wojsyk-Banaszak, I., Bręborowicz, A., Plewa, S., Pietkiewicz, D., Matysiak, J., & Klupczyńska-Gabryszak, A. (2026). Comparative analysis of amino acid profiles across pediatric groups stratified by asthma and IgE-dependent allergy showed differences in serum asparagine levels. Metabolomics, 22(5), Article 153. https://doi.org/10.1007/s11306-026-02533-2

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02533-2

Keywords: asthma, asparagine, alpha-aminobutyric acid, metabolomics, pediatrics, IgE-dependent allergy, amino acids, LC-MS/MS, biomarkers, CD8 T cells, serum analysis, childhood wheezing